logo

Outlook Therapeutics, Inc. (OTLK)



Trade OTLK now with
  Date
  Headline
8/20/2019 8:06:54 AM Outlook Therapeutics Completes Patient Enrollment For NORSE 1 A Phase 3 Clinical Trial For ONS-5010 In Wet AMD
7/16/2019 8:17:05 AM Outlook Therapeutics Doses First Patient In ONS-5010-002 Phase 3 Clinical Trial
4/10/2019 9:13:18 AM Outlook Therapeutics Prices Public Offering Of 10.34 Mln Common Shares
  
 
>